Sign in
Taking people in United StatesPhase 1

Siplizumab during liver transplant for people with autoimmune liver disease

Tests siplizumab's safety in adults with autoimmune liver disease receiving a liver transplant.

Key facts

Who runs it
Elizabeth C. Verna
Where
New York, United StatesSee the site
Trial code
Registry title
A Study of SIPLIZUMAB in AILD and LT Patients
Status
Recruiting
Phase
Phase 1
People taking part
8 people, planned
Started
11 Sept 2024
Expected to end
31 Mar 2028
Type of study
Interventional
Treatments tested
  • Siplizumab
Record updated
24 November 2025

Who can take part

The trial is looking for adults with autoimmune hepatitis (AIH) and/or primary sclerosing cholangitis (PSC) who are on the waiting list for a liver transplant. They get siplizumab around the time of the transplant.

Age
18 years or older
Sex
All sexes
Disease stage
Clinical diagnosis of AIH and/or PSC, listed for liver transplantation. People with a MELD-Na liver score above 30 at the time of transplant cannot join.
Earlier treatment
No earlier transplant. No other study drugs in the last 30 days or 5 half lives. No live-attenuated vaccine within 2 months of transplant.
Biomarker or test result
Positive blood test for Epstein-Barr virus (EBV) within 12 months of screening.
Main reasons for not taking part
  • Other significant liver disease, such as viral hepatitis, alcohol-related liver disease or biopsy-proven non-alcoholic steatohepatitis
  • Acute liver failure, listing for more than one organ, or known cancer, including cholangiocarcinoma and hepatocellular carcinoma
  • HIV-1, hepatitis B or hepatitis C infection, or untreated latent TB
  • Pregnant, breastfeeding or unwilling to use contraception
  • Kidney failure with dialysis or eGFR < 30 at transplant, or low white cell (WBC less than 2,000/mm3) or lymphocyte (< 200/mm3) counts
Show the full registry criteria (23)Hide the full registry criteria

Who can take part

  • Able to provide informed consent
  • Age ≥ 18 years old
  • Clinical diagnosis of AIH and/or PSC
  • Listed for liver transplantation
  • Epstein-Barr virus (EBV) seropositive within 12 months of screening

Who cannot take part

  • Prior transplant
  • Listed for multiorgan transplant
  • Other investigational products in the last 30 days or 5 half lives
  • Alcohol use exceeding 30g/day for men or 20g/day for women, and/or known phosphatidylethanol (PETH) level >80 in the 3 months prior to LT
  • Receipt of any live-attenuated vaccine within 2 months of transplant; ADDITIONAL exclusion criteria to be reviewed at the time of transplant
  • Presence or history of significant liver disease other than AIH or PSC, including viral hepatitis, alcohol-related liver disease and biopsy-proven non-alcoholic steatohepatitis
  • Acute liver failure
  • Known malignancy, including cholangiocarcinoma and hepatocellular carcinoma
  • Sero-positive for HIV-1
  • Hepatitis C Virus (HCV) antibody or RNA positive (within 6 months of screening)
  • HBsAg, hepatitis B virus (HBV) DNA or HBcAb positive (within 6 months of screening)
  • Untreated latent TB infection as detected by QuantiFERON Gold Plus Interferon Gamma Release Assay (IGRA) (or current standard interferon gamma release assay for TB)
  • Model for end-stage liver disease (MELD)-Na score >30
  • Donor features of Donation after Cardiac Death (DCD), HCV Ab or nucleic acid testing (NAT+), HBcAb or HBsAg+, or blood types A, B, and O incompatible organ
  • Leukopenia (WBC less than 2,000/mm3
  • Absolute lymphocyte count < 200/mm3
  • Renal failure with dialysis or with estimated glomerular filtration rate (eGFR) < 30 at the time of LT
  • Pregnant/lactating or unwilling to use contraception

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in United States.

  • Columbia University Irving Medical Center / NewYork-Presbyterian HospitalNew York, United StatesContact: Theresa Lukose, PharmDTaking people

About the trial

What the trial wants to find out

There is a significant unmet need for safe and effective therapeutic approaches to prevent immune-mediated graft injury and its complications in liver transplant (LT) recipients with autoimmune liver disease (AILD) including autoimmune hepatitis and primary sclerosing cholangitis. Siplizumab is an anti-cluster of differentiation 2 (CD2) monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD. The purpose of this pilot, open-label phase 1 study is to determine the safety of siplizumab for induction in patients with AILD undergoing LT.

Read full original descriptionShow less

Up to eight (8) subjects will receive siplizumab 0.6 mg/kg/dose on the day of transplant (Day 0) and Day 4 post-transplant, for a total of two doses.

All subjects will be followed in the study for 12 months post-LT.

The group in the trial

  • Open LabelTreatment being tested

    subjects will receive 0.6 mg/kg/dose intravenously on the day of transplant (Day 0) intraoperatively and on post-transplant Day 4.

    Treatment: Siplizumab

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A 12-Month, Open-Label Study Evaluating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Siplizumab as Induction Therapy in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation (SET-SAIL)
Plain-language title
Siplizumab during liver transplant for people with autoimmune liver diseaseGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06455280, who can take part
Record updated
24 November 2025